Literature DB >> 1605567

Population pharmacokinetics/dynamics.

L B Sheiner1, T M Ludden.   

Abstract

Mesh：

Year:  1992        PMID： 1605567     DOI： 10.1146/annurev.pa.32.040192.001153

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN： 0362-1642            Impact factor:   13.820


× No keyword cloud information.
  81 in total

1.  Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.

Authors:  M Tod; F Mentré; Y Merlé; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

Review 2.  Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

Authors:  D A Hughes; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors:  J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

4.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

5.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

6.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

Review 7.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 8.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 9.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

Review 10.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.